APP and Alzheimer disease: After administering SY orally at a dose of 30 mg/kg daily for 4 weeks to both 12-month-old APP/PS1 transgenic mice and wild-type mice exhibiting AD markers, scientists observed a marked decrease in the intensity and spread of fluorescent amyloid plaques within the cortical and hippocampal regions of the transgenic subjects.